Drug Trial Radar · NCT06571448
Efficacy, Safety, and Tolerability of SR750 in Patients With Trigeminal Neuralgia
Last checked: Nov 19, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
138
Actual
Start
Sep 16, 2024
Primary completion
Jan 26, 2026
Study completion Feb 24, 2026
Sponsor
- Lead sponsor
- Shanghai SIMR Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the efficacy,safety and tolerability of SR750 in patients with trigeminal neuralgia (TN). Patients will receive SR750 (study drug) or placebo for 6 weeks and keep a diary of daily pain. The study duration for each patient is up to 11 weeks.
Conditions
- Trigeminal Neuralgia
Interventions
SR750 tabletDrug
SR750 high dose BID orally for 6 weeks
SR750 tabletDrug
SR750 low dose BID orally for 6 weeks
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Daily Average Pain Score (DAPS)Time frame: up to week 6
Locations
1 site in 1 country. Site status is shown where the registry gives one.
China-Japan Friendship Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.